Cambridge, UK, 1st October 2026: CN Bio, a leading Organ-on-a-chip (OOC) company de-risking drug discovery and development pipelines by enabling
FDA’s plan to phase out animal testing requirement for monoclonal antibodies and other drugs with more human-relevant methods
Implementation of this new regimen will begin immediately for investigational new drug (IND) applications, where the inclusion of NAMs data is now